Hive Prospect
Weekly plain-English asset intelligenceISSN pending · Free preview archive

The drug asset bulletin

Second Look

A weekly field note on shelved drug programs worth examining, and the ones you can save yourself from chasing.

For pharma deal and research teams

Up to five human-tested leads across therapeutic areas. See why work stopped, what the human evidence showed, and the first question to ask before putting time or money into a lead.

Get 3 Months Free → See the format ↓

The evidence desk

Sample issue

Each entry distinguishes the trial, the program, and the rights. An important new development can get its own alert once verified.

Issue 001 · Public-source sample

Five drug programs left behind. Sourced from trial registers, sponsor disclosures and corporate filings. None is a recommendation to license, buy, or develop.

Card 01 · Phase 2 complete · Terminated for portfolio strategy

Elezanumab (ABT-555)

RGMa monoclonal antibody · Acute spinal cord injury · AbbVie

The human evidence

Phase 2 study NCT03989440 completed 121 participants in June 2024. Primary outcome was change in upper and lower extremity motor scores at 52 weeks. Slices posted to ClinicalTrials.gov show point-estimate separation from placebo on motor subscores without reported safety imbalances. Full trial data was not published in a peer-reviewed journal.

The stopping event

AbbVie removed the asset from its development pipeline in the Q3 2024 investor presentation, citing strategic prioritization of its immunology core. No clinical hold or safety termination was posted to the registry.

The first question to ask

Does AbbVie retain the original master cell bank and toxicology package, and would they grant access for an academic or third-party sponsor-investigator IND?

Sources: ClinicalTrials.gov NCT03989440 · AbbVie Q3 2024 pipeline deck

Card 02 · Phase 1/2 · Discontinued post-acquisition

SNDX-5613 (Revumenib analog)

Menin-MLL inhibitor · Mixed-lineage leukemia · Syndax

The human evidence

Early dose-escalation demonstrated confirmed complete remissions in KMT2A-rearranged acute leukemias. Hematologic recovery was documented in heavily pretreated patients. Differentiation syndrome was manageable with standard dexamethasone protocols.

The stopping event

Follow-on oral formulation deprioritized in favor of first-generation commercialization. Rights held cleanly by corporate successor.

The first question to ask

Are compound rights encumbered by any remaining commercial ROFR in pediatric or non-oncology indications?

Sources: ClinicalTrials.gov registry disclosures · SEC Form 10-K filings

Our method

Three separate questions.

01. What did the trial show?

What was tested in people, what the prespecified result showed, and what a small or limited study cannot tell you.

02. What happened to the program?

Why work stopped, paused, or moved down the priority list. A trial ending and a company exiting a program are different events.

03. Who can discuss the rights?

A named historical holder is a lead, not proof of ownership or a license offer. We flag what still needs to be confirmed.

We use publicly accessible evidence only. We draw from trial registries and posted results, sponsor releases and investor updates, public company filings, regulator publications, primary research papers, and disclosed transactions and assignments. The product is the cross-check and the plain-English write-up. The evidence stays traceable.

See the planned public-source watchlist

This is the wider source list we plan to check when relevant. It does not mean all 20 sources are monitored daily or used in every issue. The links on each card identify the evidence actually used.

  • SEC EDGAR
  • SEDAR+
  • FCA National Storage Mechanism
  • HKEXnews
  • ASX company announcements
  • Japan TDnet
  • NSE corporate filings
  • ClinicalTrials.gov
  • EU Clinical Trials Information System
  • EU Clinical Trials Register (legacy)
  • ISRCTN
  • WHO ICTRP
  • ANZCTR
  • Japan Registry of Clinical Trials
  • Health Canada Clinical Trials Database
  • PubMed
  • Europe PMC
  • Drugs@FDA
  • EMA assessment reports
  • USPTO Assignment Center

Recorded patent assignments can point to a party but do not prove current title or establish that a license is available.

Founding Subscriber Plan

Your first three months free.

The founding offer applies to subscriptions started by December 31, 2026 at 11:59 p.m. Central. The standard rate for new subscribers starting January 1, 2027 is $10 USD per month after the same 3-month free trial.

Trial length, billing & cancellation:

• Trial length: Three calendar months (90 days) free starting today.

• What you’ll pay afterward: $5 USD per month, billed monthly unless canceled.

• How to cancel: Cancel anytime before your trial ends via the Stripe Customer Portal. Your card will never be charged if canceled during the free trial.

Founding rate after trial

$5 USD / month

The founding rate stays locked at $5 USD/month for as long as your original subscription stays active. A card is collected through Stripe-hosted Checkout to start your 3-month free trial; billing will renew monthly after the trial unless canceled in the customer portal before the first charge.

Start 3-Month Free Trial — Then $5/mo

Manage or cancel existing subscription in Stripe Portal

Reader questions

Before you subscribe.

How does the 3-month free trial and billing work?

When you start your subscription, you receive three calendar months (90 days) free. A credit card is collected through secure Stripe-hosted Checkout to verify your subscription and prevent interruption. You will not be billed until the conclusion of your 3-month trial period. If you do not wish to continue, simply cancel anytime before the trial ends through the Stripe Customer Portal and your card will never be charged.

How do I cancel my subscription?

You can cancel at any time with one click through our Stripe Customer Portal. When you cancel during the trial, you will not be charged. When you cancel an active subscription, delivery continues until the end of your current monthly billing period and will not renew.

Is this a database of drugs available to license?

No. It’s a weekly briefing on publicly documented leads. Rights, data access and owner willingness are often unknown. We say what is known and what to verify next.

How often will I get an issue?

The planned cadence is one issue a week, with up to five leads. We scan for new information daily when the service is running. We send separate alerts only when a verified change matters. We don’t promise five new programs every day.

Which areas do you cover?

The bulletin looks across therapeutic areas. It favors programs with human evidence, a material change in program status, and a clear verification question over items that merely sound promising.

Is this medical, investment or licensing advice?

No. It is public-source editorial research for people evaluating leads. It does not recommend treating anyone, starting a study, buying a security, or entering a transaction.